SDT is safe, repeatable, and better tolerated than both chemotherapy and radiotherapy. It has been shown to have an effect in human cancer therapy, but more clinical trials are needed to establish standardized protocols for sonosensitizer delivery, treatment parameters, and combination therapies. The most appropriate timing of treatment also remains to be determined-whether to prevent recurrence in the postoperative period, or as a salvage option in patients with recurrent GBM for which redo surgery is inappropriate. It is hoped that SDT will also be developed for a wider spectrum of clinical indications, such as metastases, meningioma, and low-grade glioma. Further clinical trials are in preparation.
Keyphrases
- clinical trial
- low grade
- cancer therapy
- high grade
- endothelial cells
- early stage
- locally advanced
- radiation therapy
- drug delivery
- squamous cell carcinoma
- radiation induced
- randomized controlled trial
- open label
- high resolution
- atrial fibrillation
- left ventricular
- mass spectrometry
- aortic valve
- study protocol
- smoking cessation
- transcatheter aortic valve replacement
- surgical site infection